Furthermore, as demonstrated by the mIF, mice treated with combination therapy recruited more CD8+ T cells and decreased the proportion of PD-1+CD8+ T cells in tumor tissues (Fig. 8D, E). The gene discussed is CD8A; the disease is neoplasm.